Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invex TherapeuticsASX:IXC -4.55%30 Price-to-Tangible-Book is 1.72 as of Sep. 05, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Invex Therapeutics ranks better than 72.77% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Invex Therapeutics Price-to-Tangible-Book Related Terms
Invex Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IXC vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Invex Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Invex Therapeutics (ASX:IXC) has a Price-to-Tangible-Book of 1.72 as of Sep. 05, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #308 out of 1131 companies in the Biotechnology industry, placing it in the top 27.2%.
Is Invex Therapeutics' Price-to-Tangible-Book too high?
Invex Therapeutics' current Price-to-Tangible-Book is 1.72. The Biotechnology industry median Price-to-Tangible-Book is 3.26. Invex Therapeutics' value of 1.72 is 47.2% below this industry median. Based on the distribution chart, Invex Therapeutics ranks #308 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Invex Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #308 out of 1131 companies for Price-to-Tangible-Book. This puts Invex Therapeutics in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.26. Invex Therapeutics' value of 1.72 is 47.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invex Therapeutics's current Price-to-Tangible-Book of 1.72 is 47.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Invex Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current Price-to-Tangible-Book is 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Price-to-Tangible-Book of 1.72. The current Price-to-Tangible-Book is 1.72 and 47.2% below the Biotechnology industry median of 3.26. Invex Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Price-to-Tangible-Book is 1.72 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
30GF Score
Get the complete analysis for ASX:IXC
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 
